When: 6:00pm AEDT Wednesday 10 November 2021
Presented by: Prof Robert Booy and Dr Andrew Baird
Accreditation: This webinar is accredited with RACGP (ID: 305628) & ACRRM (ID: 24536)
Hosted by the Immunisation Coalition, this webinar is produced by Praxhub and is for HCPs only. To register, you will be required to login or register with Praxhub. When logging in, you will be automatically directed to the webinar registration page. Simply click on the red “Register” button to complete the process. Your confirmation details with webinar access link will be automatically sent from Zoom.
Dr. Andrew Baird is a General Practitioner in Elwood, Melbourne and a tutor in Professional Practice for medical students at University of Melbourne. He has a background in rural general practice. His interests are in general practice and medical education.
Professor Robert Booy is an infectious diseases paediatrician. Since 2005 he has worked at the University of Sydney in the fields of vaccinology, epidemiology and infectious diseases. He is currently a Senior Professorial Fellow at the University of Sydney Children’s Hospital Westmead Clinical School. From 2005 to 2019 he held the position of Head of Clinical Research at the National Centre for Immunisation Research and Surveillance (NCIRS) at Westmead Children’s Hospital and remains an Affiliate of NCIRS.
2021 Shingles Vaccination Update for Frontline Healthcare Professionals
This webinar will provide attendees with an update regarding shingles epidemiology and current trends in vaccination rates.
Low shingles vaccination rates in Australian adults impact the epidemiology of the disease. This webinar will explore what current guidelines advise regarding improving pertussis vaccination rates in Australia, and therefore reducing disease burden and complications.
It will discuss the two shingles vaccinations available in Australia, comparing efficacy, safety, dosage regimens and indications for each vaccine.
- Describe the epidemiology of shingles in various population groups, including persons aged over 65 years
- Outline current vaccination rates in older Australians, and recognised strategies for improving uptake of shingles vaccines
- Explain the possible clinical sequelae associated with shingles, including serious complications, impact on quality of life, and the particular risk attributed to persons aged over 80 years
- Identify the patients in whom shingles vaccination is a priority, based on age and medical comorbidities
- Describe and compare the two shingles vaccines currently available in Australia, including safety profiles, efficacy, dosage regimens and costs